Hepion Pharmaceuticals to Present Data on Synergistic Effects of Rencofilstat with Anti-PD1 at AACR 2023
17 Abril 2023 - 5:15PM
Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage
biopharmaceutical company focused on Artificial Intelligence
(“AI”)-driven therapeutic drug development for the treatment of
fibrotic diseases, including non-alcoholic steatohepatitis
(“NASH”), hepatocellular carcinoma (“HCC”), and other chronic
diseases, announced that an abstract highlighting its lead drug
candidate, rencofilstat, will be presented by its Chief Scientific
Officer, Daren Ure, PhD, at the American Association for Cancer
Research Annual Meeting, which is being held April 15-19, 2023, in
Orlando, Florida.
Poster Presentation Details
Title: Rencofilstat Exerts a
Dominant Role in Synergistic Anti-PD1-Combination Effects in a
Fatty Liver Model of Hepatocellular Carcinoma
Authors: Ure D, Leslie J, Haddon L, Variya B,
Fu C, Mann J, Mann D
Date: Tuesday, April 18, 2023
Time: 9:00 AM - 12:30 PM ET
A copy of the presentation materials will be
accessible on the Company’s website at www.hepionpharma.com under
“Publications” in the Pipeline section.
About Hepion
Pharmaceuticals
The Company’s lead drug candidate, rencofilstat,
is a potent inhibitor of cyclophilins, which are involved in many
disease processes. Rencofilstat has been shown to reduce liver
fibrosis and hepatocellular carcinoma tumor burden in experimental
disease models and is currently in Phase 2 clinical development for
the treatment of NASH. In November 2021, the U.S. Food and Drug
Administration (“FDA”) granted Fast Track designation for
rencofilstat for the treatment of NASH. That was followed in June
2022 by the FDA’s granting of Orphan Drug designation to
rencofilstat for the treatment of HCC.
Hepion has created a proprietary AI platform,
called AI-POWR™, which stands for Artificial
Intelligence – Precision
Medicine; Omics (including genomics, proteomics,
metabolomics, transcriptomics, and lipidomics);
World database access; and
Response and clinical outcomes. Hepion intends to
use AI-POWR™ to help identify which NASH patients will best respond
to rencofilstat, potentially shortening development timelines and
increasing the observable differences between placebo and treatment
groups. In addition to using AI-POWR™ to drive its ongoing NASH
clinical development program, Hepion intends to use the platform to
identify additional potential indications for rencofilstat to
expand the company’s footprint in the cyclophilin inhibition
therapeutic space.
For further information, please contact:
Stephen KilmerHepion Pharmaceuticals Investor
RelationsDirect: (646)
274-3580skilmer@hepionpharma.com
Hepion Pharmaceuticals (NASDAQ:HEPA)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Hepion Pharmaceuticals (NASDAQ:HEPA)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024